Subscribe To

Price Alert Latest News Economic Calendar News

OCGN / Ocugen stock drops after FDA places clinical hold on study of COVID-19 vaccine candidate Covaxin

Shares of Ocugen Inc. OCGN, -2.03% sank 6.9% premarket, after the biotechnology company said the U.S. Food and Drug Administration placed a "clinical hold" on the Phase 2/3 study of its COVID-19 vaccine candidate Covaxin. Ocugen said the hold was the result of its decision to temporarily pause dosing participants in the study while it evaluates World Health Organization statements following their inspection of Bharat Biotech International Ltd. Read More

Demo Live Account See Partner Details

Content Topics

Ocugen

Stock

Drops

After

Places

Clinical

Hold

Study

Covid

19 Covid 19

Vaccine

Candidate

Covaxin

OCGN

Posted: Apr 12 2022, 09:11

Author Name: Market Watch

OCGN News

By InvestorPlace
October 10, 2023

Why Is Ocugen (OCGN) Stock Up 5% Today?

Ocugen (NASDAQ: OCGN ) stock is on the rise Tuesday after the clinical-stage biopharmaceutical company announced a new vaccine trial. According to a p

By GlobeNewsWire
August 18, 2023

Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results

MALVERN, Pa., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, d

By InvestorPlace
June 5, 2023

Can Pat Toomey Save Ocugen (OCGN) Stock?

Shares of Ocugen (NASDAQ: OCGN ) stock have been on the move today. Following a surge of more than 3% this morning, shares of OCGN stock have since

By InvestorPlace
May 24, 2023

5 Investors Betting Big on Ocugen (OCGN) Stock Right Now

Ocugen (NASDAQ: OCGN ) stock has trended steadily downward for the past six months, shedding almost 70% of its value. While things have looked bleak f

By InvestorPlace
May 24, 2023

Why Is Ocugen (OCGN) Stock Down 22% Today?

Ocugen (NASDAQ: OCGN ) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering. Ocugen has announced that

By GlobeNewsWire
May 23, 2023

Ocugen to Present at BIO International Convention 2023

MALVERN, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, de

By InvestorPlace
April 14, 2023

Why Is Ocugen (OCGN) Stock Moving Today?

Ocugen (NASDAQ: OCGN ) stock is on the move Friday after the company revealed preliminary results from an ongoing clinical trial. The preliminary resu

By The Motley Fool
February 28, 2023

Why Ocugen Stock Eked Out a Win Today

The company is clearly progressing on several fronts with its pipeline programs.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.